Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacodynamics: Which trails are your drugs taking?

Literature DB >> 25894084

Pharmacodynamics: Which trails are your drugs taking?

Rumin Zhang¹.

Abstract

Mesh：

Substances：

Year: 2015 PMID： 25894084 DOI： 10.1038/nchembio.1795

Source DB: PubMed Journal: Nat Chem Biol ISSN： 1552-4450 Impact factor: 15.040

× No keyword cloud information.

7 in total

1. In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis.

Authors: Rumin Zhang; William T Windsor
Journal: Methods Mol Biol Date: 2013

Review 2. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.

Authors: Rumin Zhang; Frederick Monsma
Journal: Expert Opin Drug Discov Date: 2010-09-16 Impact factor: 6.098

3. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time.

Authors: Georges Vauquelin
Journal: Expert Opin Drug Discov Date: 2010-08-17 Impact factor: 6.098

4. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

Authors: Robert A Copeland
Journal: Expert Opin Drug Discov Date: 2010-04 Impact factor: 6.098

5. A universal homogeneous assay for high-throughput determination of binding kinetics.

Authors: Felix Schiele; Pelin Ayaz; Amaury Fernández-Montalván
Journal: Anal Biochem Date: 2014-09-18 Impact factor: 3.365

6. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors: Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal: J Pharm Pharm Sci Date: 2014 Impact factor: 2.327

Review 7. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety.

Authors: David C Swinney
Journal: Curr Top Med Chem Date: 2006 Impact factor: 3.295

7 in total

10 in total

Review 1. The drug-target residence time model: a 10-year retrospective.

Authors: Robert A Copeland
Journal: Nat Rev Drug Discov Date: 2015-12-18 Impact factor: 84.694

2. Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Authors: Lauren A Spagnuolo; Sandra Eltschkner; Weixuan Yu; Fereidoon Daryaee; Shabnam Davoodi; Susan E Knudson; Eleanor K H Allen; Jonathan Merino; Annica Pschibul; Ben Moree; Neil Thivalapill; James J Truglio; Joshua Salafsky; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal: J Am Chem Soc Date: 2017-02-22 Impact factor: 15.419

Pharmacodynamics: Which trails are your drugs taking?

1. In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis.

Review 2. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.

3. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time.

4. The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety.

5. A universal homogeneous assay for high-throughput determination of binding kinetics.

6. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Review 7. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety.

Review 1. The drug-target residence time model: a 10-year retrospective.

2. Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Review 3. Link between a high k _on for drug binding and a fast clinical action: to be or not to be?

4. Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Review 5. Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

6. Endless Resistance. Endless Antibiotics?

7. Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.

8. Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.

9. vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding.

Review 10. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Review 2. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.

Review 7. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety.

Review 1. The drug-target residence time model: a 10-year retrospective.

Review 3. Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Review 5. Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Review 10. International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Review 3. Link between a high k _on for drug binding and a fast clinical action: to be or not to be?